CRIS Current Research Information System

VENTURI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.880
AS - Asia 3.061
EU - Europa 2.562
SA - Sud America 212
AF - Africa 199
Continente sconosciuto - Info sul continente non disponibili 191
OC - Oceania 5
Totale 10.110
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.783
VN - Vietnam 831
SG - Singapore 800
CN - Cina 739
GB - Regno Unito 648
IT - Italia 461
SE - Svezia 347
DE - Germania 322
HK - Hong Kong 214
FR - Francia 161
IN - India 142
BR - Brasile 140
RU - Federazione Russa 129
NL - Olanda 114
IE - Irlanda 84
ZA - Sudafrica 68
JP - Giappone 67
TG - Togo 58
EE - Estonia 51
CH - Svizzera 47
CA - Canada 45
FI - Finlandia 44
UA - Ucraina 44
KR - Corea 38
JO - Giordania 35
BG - Bulgaria 31
BD - Bangladesh 30
NG - Nigeria 30
PH - Filippine 28
AR - Argentina 27
CI - Costa d'Avorio 22
IR - Iran 20
IQ - Iraq 19
TH - Thailandia 19
BE - Belgio 17
PL - Polonia 15
MX - Messico 13
EC - Ecuador 12
JM - Giamaica 12
VE - Venezuela 11
AT - Austria 10
TR - Turchia 10
TW - Taiwan 10
ID - Indonesia 9
LB - Libano 8
ES - Italia 7
GR - Grecia 7
PK - Pakistan 7
SA - Arabia Saudita 7
SC - Seychelles 7
CR - Costa Rica 6
UZ - Uzbekistan 6
AU - Australia 5
CL - Cile 5
CO - Colombia 5
PE - Perù 5
TN - Tunisia 5
MY - Malesia 4
PT - Portogallo 4
PY - Paraguay 4
QA - Qatar 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
GT - Guatemala 3
HN - Honduras 3
KZ - Kazakistan 3
LT - Lituania 3
MA - Marocco 3
NI - Nicaragua 3
BO - Bolivia 2
CZ - Repubblica Ceca 2
EU - Europa 2
KH - Cambogia 2
LV - Lettonia 2
OM - Oman 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
BZ - Belize 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GP - Guadalupe 1
IL - Israele 1
KE - Kenya 1
LC - Santa Lucia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
NP - Nepal 1
PR - Porto Rico 1
RS - Serbia 1
SN - Senegal 1
Totale 9.919
Salva come PNG Salva come JPEG
Città #
Southend 597
Singapore 539
Ashburn 421
Chandler 358
Fairfield 258
San Jose 243
Hong Kong 202
Ho Chi Minh City 174
Beijing 163
Houston 160
Seattle 140
Woodbridge 139
Hanoi 136
Wilmington 135
Dong Ket 117
Princeton 116
Ann Arbor 110
Santa Clara 92
Cambridge 87
Bologna 86
Dublin 84
Boardman 83
New York 83
Council Bluffs 77
Lomé 58
Nanjing 56
Lauterbourg 55
Tokyo 55
Westminster 54
Los Angeles 52
Padova 51
Hefei 45
Medford 43
Bern 42
Chicago 39
Amman 35
Frankfurt am Main 34
Helsinki 30
Milan 30
Sofia 30
Munich 29
São Paulo 28
Abeokuta 27
Buffalo 27
Redmond 27
Bremen 26
Hebei 26
Seoul 26
Jinan 24
Shenyang 24
Abidjan 22
Haiphong 22
Redondo Beach 22
Saint Petersburg 22
Berlin 21
Da Nang 21
San Diego 20
Jiaxing 18
Brussels 17
Phoenix 17
Rome 17
Dallas 16
Falls Church 16
Johannesburg 16
Redwood City 16
Nanchang 15
Changsha 14
Guangzhou 14
Orem 14
Shanghai 14
Tianjin 14
Turin 14
Nuremberg 13
Atlanta 12
Baghdad 12
Tehran 11
Florence 10
Montreal 10
Mountain View 10
Norwalk 10
Turku 10
Zhengzhou 10
Falkenstein 9
Kingston 9
Paris 9
Toronto 9
Denver 8
Quito 8
Bangkok 7
Dearborn 7
Hải Dương 7
London 7
Ningbo 7
San Francisco 7
Warsaw 7
Amsterdam 6
Bengaluru 6
Brescia 6
Brooklyn 6
Bến Tre 6
Totale 6.194
Salva come PNG Salva come JPEG
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 307
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 256
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 239
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 235
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 230
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 226
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 224
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 222
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 218
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 203
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 196
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 194
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 194
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 193
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 188
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 187
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 185
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 184
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 183
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 180
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 179
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease 178
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 177
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 173
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 169
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 169
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 169
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 168
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 167
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 167
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 165
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 164
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 163
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 163
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 161
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 160
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 158
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 155
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 153
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 153
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 152
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 150
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 149
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 149
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 148
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 148
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 146
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 146
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 143
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 135
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 133
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 133
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 127
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 127
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 125
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 123
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 116
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 104
null 76
Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers 25
Totale 10.110
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022907 0 0 0 86 123 71 11 49 56 88 195 228
2022/20231.300 153 197 49 177 107 112 34 81 207 26 85 72
2023/2024347 11 60 21 36 21 88 14 29 23 15 10 19
2024/20251.227 48 186 124 105 123 44 101 30 22 150 53 241
2025/20262.899 244 188 221 154 347 140 261 107 805 252 94 86
2026/2027548 85 125 271 67 0 0 0 0 0 0 0 0
Totale 10.110